Seungtaek Choi, MD
Basic profileThe University of Texas MD Anderson Cancer Center
Seungtaek Choi is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 24 publications with 342 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 5 Dec 2014.
Clinical trials
- Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Sponsor: M.D. Anderson Cancer Center
- Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
Sponsor: M.D. Anderson Cancer Center
- Study of Quality of Life for Prostate Proton Therapy
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Sumitomo Pharma America, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
71.8%alpha-Adrenergic Blocker71.8%Tamsulosin Hcl100%Part D≥25 patientsCancer & immunology
28.2%Androgen Receptor Inhibitor28.2%Bicalutamide100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder.
Journal of Clinical Oncology
2026 - External beam radiation therapy for salvage after focal therapy as primary treatment in prostate adenocarcinoma.
Journal of Clinical Oncology
2025 - Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer
Clinical and Translational Radiation Oncology
2024 - Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver Variability
International Journal of Radiation Oncology*Biology*Physics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”